We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI-Powered Immuno-Oncology Tool Predicts Lung Cancer Treatment Outcomes

By LabMedica International staff writers
Posted on 02 Dec 2024
Print article
Image: HistoTME reads routinely stained histopathology images of tumor samples (Photo courtesy of Adobe Stock)
Image: HistoTME reads routinely stained histopathology images of tumor samples (Photo courtesy of Adobe Stock)

Immune checkpoint inhibitors (ICI) are used to treat non-small cell lung cancer (NSCLC) by enhancing the immune system's ability to fight cancer. However, identifying which patients will benefit most from this treatment remains a challenge. Now, advancements in artificial intelligence (AI) and diagnostic tools offer the potential to enhance treatment outcomes and survival rates for NSCLC patients by helping doctors more accurately predict their response to ICI therapy.

Researchers at SUNY Upstate Medical University (Syracuse, NY, USA) have developed HistoTME, an affordable and easy-to-implement AI tool. This advanced deep learning algorithm analyzes routinely stained histopathology images of tumor samples to predict molecular subtypes (based on bulk RNA sequencing), providing insights into the tumor microenvironment (TME). By examining these pathology images, HistoTME identifies specific cell types in the surrounding tumor tissue, offering valuable information about the patient's unique TME composition. This is crucial for predicting personalized ICI treatment responses, especially in patients with low PD-L1 expression, a key marker commonly used in companion diagnostics. The algorithm was validated on a multi-modal dataset comprising over 650 lung cancer patients and more than 1500 images.

The researchers hope this method will assist doctors in selecting personalized treatment plans with greater accuracy and cost-efficiency, especially for patients without access to expensive molecular testing. Moreover, this test could complement existing companion diagnostics, which often struggle to identify the appropriate patients for the right treatments. The next phase of the study will involve clinical validation of HistoTME, which will further evaluate its effectiveness in real-world clinical environments and may lead to its integration into routine cancer care.

“AI-driven diagnostics and prognostication have the potential to transform the future of healthcare practices and precision oncology,” said Upstate researcher Tamara Jamaspishvili, MD/PhD, who won the "Best Research Poster" Award for Faculty at the Digital Pathology Association's national conference, PathVisions 2024 for her work using AI and computational pathology to improve cancer diagnosis and treatment.

Gold Member
Troponin T QC
Troponin T Quality Control
New
Gold Member
Strep Pneumoniae Rapid Test
Strep Pneumoniae (6503 – 6573)
New
Chikungunya Rapid Test
Chikungunya IgG/IgM Rapid Test Kit
New
Hematology Analyzer
BH-6180

Print article

Channels

Molecular Diagnostics

view channel
Image: A simple blood test could transform how asthma is identified and monitored (Photo courtesy of 123RF)

Simple Blood Test Diagnoses Asthma and Determines Severity

Currently, diagnosing asthma requires advanced breathing tests, typically available only at specialized centers, which can be challenging for young children. While existing treatments like inhaled steroids... Read more

Microbiology

view channel
Image: The breakthrough system offers a faster way to diagnose bloodborne infections (Photo courtesy of Melio)

Culture-Free Platform Rapidly Identifies Blood Stream Infections

Neonatal sepsis is a life-threatening condition that results from bloodstream infections in newborns under 28 days old. Due to their immature immune systems, newborns are especially vulnerable to infections.... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more

Industry

view channel
Image: The game-changing immunoassay diagnostics platform delivers results from whole blood sample in 10 minutes (Photo courtesy of SpinChip)

bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics

bioMérieux (Marcy l’Étoile, France) has agreed to acquire SpinChip Diagnostics (Oslo, Norway), the developer of a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.